ReviewBritish journal of clinical pharmacology2015
Clinical pharmacology = disease progression + drug action.
Review in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.Medicine · 2016Trial
- Model-Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model-Based Longitudinal HbA1c Meta-Analysis from EMA Marketing Authorization Applications.Clinical pharmacology and therapeutics · 2026Article
- Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.CPT: pharmacometrics & systems pharmacology · 2022Article
- Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.The AAPS journal · 2020Article
- Applying Beta Distribution in Analyzing Bounded Outcome Score Data.The AAPS journal · 2020Article
- Liver Microphysiological Systems for Predicting and Evaluating Drug Effects.Clinical pharmacology and therapeutics · 2019Review
- Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.The AAPS journal · 2018Article
- The pharmaceutical industry needs more clinical pharmacologists.British journal of clinical pharmacology · 2017Article
- Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats.Frontiers in physiology · 2016Article
- Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.CPT: pharmacometrics & systems pharmacology · 2015Article
- Pharmacometrics: so much mathematics and why planes achieve their destinations with almost perfect results ….British journal of clinical pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical pharmacology is concerned with understanding how to use medicines to treat disease. Pharmacokinetics and pharmacodynamics have provided powerful methodologies for describing the time course of concentration and effect in individuals and in populations. This population approach may also be applied to describing the progression of disease and the action of drugs to change disease progress. Quantitative models for symptomatic and disease-modifying effects of drugs are valuable not only for describing drugs and diseases but also for identifying criteria to distinguish between types of drug actions, with implications for regulatory decisions and long-term patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.